Although cyclosporine is widely used to prevent rejection in organ transplant recipients over the long term, two problems remain for heart transplant patients: acute rejection, which occurs within the first three months after transplantation, and cardiac allograft vasculopathy, a thickening of the heart wall that can restrict blood flow.
Findings from the second year of a multi-center study of the new anti-rejection drug everolimus were presented Thursday (April 22, 2004) at the International Society for Heart and Lung Transplantation. According to lead author Howard Eisen, M.D., professor of medicine at Temple University School of Medicine and medical director of cardiac transplant at Temple University Hospital, everolimus is not only more effective, but also safer than standard therapy in preventing heart transplant rejection.
"Our findings over a two-year period reinforce what we learned in the first year of this study, as well as add to our understanding of everolimus. When combined with cyclosporine and steroids, everolimus prevents transplant rejection and lowers risk of infection and other complications better than the current standard anti-rejection therapy," said Eisen.
Eryn Jelesiewicz | EurekAlert!
Spanish scientists create a 3-D bioprinter to print human skin
24.01.2017 | Carlos III University of Madrid
Tracking movement of immune cells identifies key first steps in inflammatory arthritis
23.01.2017 | Massachusetts General Hospital
A Swedish-German team of researchers has cleared up a key process for the artificial production of silk. With the help of the intense X-rays from DESY's...
For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.
According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
24.01.2017 | Physics and Astronomy
24.01.2017 | Life Sciences
24.01.2017 | Health and Medicine